Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 256

1.

Whether to push or pull? Nicotine reduction and non-combusted alternatives - Two strategies for reducing smoking and improving public health.

Smith TT, Hatsukami DK, Benowitz NL, Colby SM, McClernon FJ, Strasser AA, Tidey JW, White CM, Donny EC.

Prev Med. 2018 Mar 29. pii: S0091-7435(18)30110-5. doi: 10.1016/j.ypmed.2018.03.021. [Epub ahead of print]

PMID:
29604326
2.

Strong preference for mint snus flavor among research participants.

Schneller LM, Lindgren BR, Shields PG, Hatsukami DK, O'Connor RJ.

Addict Behav Rep. 2017 Jul 31;6:51-55. doi: 10.1016/j.abrep.2017.07.004. eCollection 2017 Dec.

3.

Biomarkers of Potential Harm: Summary of an FDA-Sponsored Public Workshop.

Chang CM, Cheng YC, Cho M, Mishina E, Del Valle-Pinero AY, van Bemmel D, Hatsukami DK.

Nicotine Tob Res. 2017 Dec 14. doi: 10.1093/ntr/ntx273. [Epub ahead of print]

PMID:
29253243
4.

Effects of Filter Ventilation on Behavioral Economic Demand for Cigarettes: A Preliminary Investigation.

Stein JS, Koffarnus MN, O'Connor RJ, Hatsukami DK, Bickel WK.

Nicotine Tob Res. 2017 Jul 23. doi: 10.1093/ntr/ntx164. [Epub ahead of print]

PMID:
29065197
5.

Consortium on Methods Evaluating Tobacco: Research Tools to Inform FDA Regulation of Snus.

Berman ML, Bickel WK, Harris AC, LeSage MG, O'Connor RJ, Stepanov I, Shields PG, Hatsukami DK.

Nicotine Tob Res. 2017 Oct 4. doi: 10.1093/ntr/ntx228. [Epub ahead of print]

PMID:
29059363
6.

Evaluating the utility of subjective effects measures for predicting product sampling, enrollment, and retention in a clinical trial of a smokeless tobacco product.

O'Connor RJ, Lindgren BR, Schneller LM, Shields PG, Hatsukami DK.

Addict Behav. 2018 Jan;76:95-99. doi: 10.1016/j.addbeh.2017.07.025. Epub 2017 Jul 14.

PMID:
28772248
7.

Perceived nicotine content of reduced nicotine content cigarettes is a correlate of perceived health risks.

Pacek LR, Joseph McClernon F, Denlinger-Apte RL, Mercincavage M, Strasser AA, Dermody SS, Vandrey R, Smith TT, Nardone N, Hatsukami DK, Koopmeiners JS, Kozink RV, Donny EC.

Tob Control. 2017 Jul 22. pii: tobaccocontrol-2017-053689. doi: 10.1136/tobaccocontrol-2017-053689. [Epub ahead of print]

PMID:
28735272
8.

High Level of Tobacco Carcinogen-Derived DNA Damage in Oral Cells Is an Independent Predictor of Oral/Head and Neck Cancer Risk in Smokers.

Khariwala SS, Ma B, Ruszczak C, Carmella SG, Lindgren B, Hatsukami DK, Hecht SS, Stepanov I.

Cancer Prev Res (Phila). 2017 Sep;10(9):507-513. doi: 10.1158/1940-6207.CAPR-17-0140. Epub 2017 Jul 5.

9.

Reducing tobacco-related harm: FDA's proposed product standard for smokeless tobacco.

Berman ML, Hatsukami DK.

Tob Control. 2017 Jun 20. pii: tobaccocontrol-2016-053612. doi: 10.1136/tobaccocontrol-2016-053612. [Epub ahead of print]

PMID:
28634163
10.

Sex differences in physiological response to the combination of stress and smoking.

Kotlyar M, Thuras P, Hatsukami DK, al'Absi M.

Int J Psychophysiol. 2017 Aug;118:27-31. doi: 10.1016/j.ijpsycho.2017.05.008. Epub 2017 May 23.

PMID:
28549539
11.

Cigarette Filter Ventilation and its Relationship to Increasing Rates of Lung Adenocarcinoma.

Song MA, Benowitz NL, Berman M, Brasky TM, Cummings KM, Hatsukami DK, Marian C, O'Connor R, Rees VW, Woroszylo C, Shields PG.

J Natl Cancer Inst. 2017 Dec 1;109(12). doi: 10.1093/jnci/djx075. Review.

PMID:
28525914
12.

Internalized smoking stigma in relation to quit intentions, quit attempts, and current e-cigarette use.

O'Connor RJ, Rees VW, Rivard C, Hatsukami DK, Cummings KM.

Subst Abus. 2017 Jul-Sep;38(3):330-336. doi: 10.1080/08897077.2017.1326999. Epub 2017 May 8.

PMID:
28481713
13.

Cigarette Nicotine Content as a Moderator of the Relationship Between Negative Affect and Smoking.

Robinson JD, Kypriotakis G, Karam-Hage M, Green CE, Hatsukami DK, Cinciripini PM, Donny EC.

Nicotine Tob Res. 2017 Sep 1;19(9):1080-1086. doi: 10.1093/ntr/ntx068.

PMID:
28371900
14.

Low Cotinine Glucuronidation Results in Higher Serum and Saliva Cotinine in African American Compared to White Smokers.

Murphy SE, Sipe CJ, Choi K, Raddatz LM, Koopmeiners JS, Donny EC, Hatsukami DK.

Cancer Epidemiol Biomarkers Prev. 2017 Jul;26(7):1093-1099. doi: 10.1158/1055-9965.EPI-16-0920. Epub 2017 Mar 6.

PMID:
28264876
15.

Timing of nicotine lozenge administration to minimize trigger induced craving and withdrawal symptoms.

Kotlyar M, Lindgren BR, Vuchetich JP, Le C, Mills AM, Amiot E, Hatsukami DK.

Addict Behav. 2017 Aug;71:18-24. doi: 10.1016/j.addbeh.2017.02.018. Epub 2017 Feb 10.

PMID:
28235705
16.

Biomarkers of Tobacco Exposure: Summary of an FDA-Sponsored Public Workshop.

Chang CM, Edwards SH, Arab A, Del Valle-Pinero AY, Yang L, Hatsukami DK.

Cancer Epidemiol Biomarkers Prev. 2017 Mar;26(3):291-302. doi: 10.1158/1055-9965.EPI-16-0675. Epub 2016 Nov 9.

17.

Reduced nicotine content cigarettes and use of alternative nicotine products: exploratory trial.

Hatsukami DK, Luo X, Dick L, Kangkum M, Allen SS, Murphy SE, Hecht SS, Shields PG, al'Absi M.

Addiction. 2017 Jan;112(1):156-167. doi: 10.1111/add.13603. Epub 2016 Nov 2.

18.

Impact of smoking reduced nicotine content cigarettes on sensitivity to cigarette price: further results from a multi-site clinical trial.

Smith TT, Cassidy RN, Tidey JW, Luo X, Le CT, Hatsukami DK, Donny EC.

Addiction. 2017 Feb;112(2):349-359. doi: 10.1111/add.13636. Epub 2016 Nov 28.

19.

Optimized Liquid Chromatography Nanoelectrospray-High-Resolution Tandem Mass Spectrometry Method for the Analysis of 4-Hydroxy-1-(3-pyridyl)-1-butanone-Releasing DNA Adducts in Human Oral Cells.

Ma B, Ruszczak C, Jain V, Khariwala SS, Lindgren B, Hatsukami DK, Stepanov I.

Chem Res Toxicol. 2016 Nov 21;29(11):1849-1856. Epub 2016 Oct 12.

20.

Effects of 6-Week Use of Reduced-Nicotine Content Cigarettes in Smokers With and Without Elevated Depressive Symptoms.

Tidey JW, Pacek LR, Koopmeiners JS, Vandrey R, Nardone N, Drobes DJ, Benowitz NL, Dermody SS, Lemieux A, Denlinger RL, Cassidy R, al'Absi M, Hatsukami DK, Donny EC.

Nicotine Tob Res. 2017 Jan;19(1):59-67. Epub 2016 Aug 3.

21.

Evaluation of a reduced nicotine product standard: Moderating effects of and impact on cannabis use.

Pacek LR, Vandrey R, Dermody SS, Denlinger-Apte RL, Lemieux A, Tidey JW, McClernon FJ, Bangdiwala AS, Drobes DJ, al'Absi M, Strasser AA, Koopmeiners JS, Hatsukami DK, Donny EC.

Drug Alcohol Depend. 2016 Oct 1;167:228-32. doi: 10.1016/j.drugalcdep.2016.08.620. Epub 2016 Aug 28.

22.

Application of the Smokeless Tobacco Expectancies Questionnaire to Snus.

Adkison SE, Bansal-Travers M, Rees VW, Hatsukami DK, Cummings KM, O'Connor RJ.

Am J Health Behav. 2016 Sep;40(5):652-8. doi: 10.5993/AJHB.40.5.12.

23.

Reduced nicotine content cigarettes, e-cigarettes and the cigarette end game.

Benowitz NL, Donny EC, Hatsukami DK.

Addiction. 2017 Jan;112(1):6-7. doi: 10.1111/add.13534. Epub 2016 Aug 23. No abstract available.

24.

Genetic Risk Can Be Decreased: Quitting Smoking Decreases and Delays Lung Cancer for Smokers With High and Low CHRNA5 Risk Genotypes - A Meta-Analysis.

Chen LS, Baker T, Hung RJ, Horton A, Culverhouse R, Hartz S, Saccone N, Cheng I, Deng B, Han Y, Hansen HM, Horsman J, Kim C, Rosenberger A, Aben KK, Andrew AS, Chang SC, Saum KU, Dienemann H, Hatsukami DK, Johnson EO, Pande M, Wrensch MR, McLaughlin J, Skaug V, van der Heijden EH, Wampfler J, Wenzlaff A, Woll P, Zienolddiny S, Bickeböller H, Brenner H, Duell EJ, Haugen A, Brüske I, Kiemeney LA, Lazarus P, Le Marchand L, Liu G, Mayordomo J, Risch A, Schwartz AG, Teare MD, Wu X, Wiencke JK, Yang P, Zhang ZF, Spitz MR, Amos CI, Bierut LJ.

EBioMedicine. 2016 Sep;11:219-226. doi: 10.1016/j.ebiom.2016.08.012. Epub 2016 Aug 10.

25.

Harnessing the Power of Cruciferous Vegetables: Developing a Biomarker for Brassica Vegetable Consumption Using Urinary 3,3'-Diindolylmethane.

Fujioka N, Ransom BW, Carmella SG, Upadhyaya P, Lindgren BR, Roper-Batker A, Hatsukami DK, Fritz VA, Rohwer C, Hecht SS.

Cancer Prev Res (Phila). 2016 Oct;9(10):788-793. Epub 2016 Aug 18.

26.

A review of the additive health risk of cannabis and tobacco co-use.

Meier E, Hatsukami DK.

Drug Alcohol Depend. 2016 Sep 1;166:6-12. doi: 10.1016/j.drugalcdep.2016.07.013. Epub 2016 Jul 25. Review.

PMID:
27476751
27.

Estimations and predictors of non-compliance in switchers to reduced nicotine content cigarettes.

Nardone N, Donny EC, Hatsukami DK, Koopmeiners JS, Murphy SE, Strasser AA, Tidey JW, Vandrey R, Benowitz NL.

Addiction. 2016 Dec;111(12):2208-2216. doi: 10.1111/add.13519. Epub 2016 Aug 1.

28.

The case for the WHO Advisory Note, Global Nicotine Reduction Strategy.

Hatsukami DK, Zaatari G, Donny E.

Tob Control. 2017 Mar;26(e1):e29-e30. doi: 10.1136/tobaccocontrol-2016-053134. Epub 2016 Jun 29. No abstract available.

PMID:
27357938
29.

Bupropion and naltrexone for smoking cessation: A double-blind randomized placebo-controlled clinical trial.

Mooney ME, Schmitz JM, Allen S, Grabowski J, Pentel P, Oliver A, Hatsukami DK.

Clin Pharmacol Ther. 2016 Oct;100(4):344-52. doi: 10.1002/cpt.402. Epub 2016 Jun 20.

30.

Fetal Exposure to Carcinogens With Tobacco Use in Pregnancy: Phase 1 MAW Study Findings.

Flanagan CA, Koller KR, Wolfe AW, Thomas TK, Benowitz NL, Renner CC, Hughes C, Hatsukami DK, Bronars C, Murphy NJ, Day G, Decker PA, Patten CA.

Nicotine Tob Res. 2016 Nov;18(11):2162-2168. Epub 2016 May 17.

31.

Persistence and amplitude of cigarette demand in relation to quit intentions and attempts.

O'Connor RJ, Heckman BW, Adkison SE, Rees VW, Hatsukami DK, Bickel WK, Cummings KM.

Psychopharmacology (Berl). 2016 Jun;233(12):2365-71. doi: 10.1007/s00213-016-4286-x. Epub 2016 Apr 6.

32.

Nicotine and Anatabine Exposure from Very Low Nicotine Content Cigarettes.

Denlinger RL, Smith TT, Murphy SE, Koopmeiners JS, Benowitz NL, Hatsukami DK, Pacek LR, Colino C, Cwalina SN, Donny EC.

Tob Regul Sci. 2016 Apr;2(2):186-203. doi: 10.18001/TRS.2.2.9.

33.

Cognitive testing of tobacco use items for administration to patients with cancer and cancer survivors in clinical research.

Land SR, Warren GW, Crafts JL, Hatsukami DK, Ostroff JS, Willis GB, Chollette VY, Mitchell SA, Folz JN, Gulley JL, Szabo E, Brandon TH, Duffy SA, Toll BA.

Cancer. 2016 Jun 1;122(11):1728-34. doi: 10.1002/cncr.29964. Epub 2016 Mar 28.

34.

The Impact of Smoking Very Low Nicotine Content Cigarettes on Alcohol Use.

Dermody SS, Tidey JW, Denlinger RL, Pacek LR, al'Absi M, Drobes DJ, Hatsukami DK, Vandrey R, Donny EC.

Alcohol Clin Exp Res. 2016 Mar;40(3):606-15. doi: 10.1111/acer.12980. Epub 2016 Feb 25.

35.

Research Priorities, Measures, and Recommendations for Assessment of Tobacco Use in Clinical Cancer Research.

Land SR, Toll BA, Moinpour CM, Mitchell SA, Ostroff JS, Hatsukami DK, Duffy SA, Gritz ER, Rigotti NA, Brandon TH, Prindiville SA, Sarna LP, Schnoll RA, Herbst RS, Cinciripini PM, Leischow SJ, Dresler CM, Fiore MC, Warren GW.

Clin Cancer Res. 2016 Apr 15;22(8):1907-13. doi: 10.1158/1078-0432.CCR-16-0104. Epub 2016 Feb 17.

36.

Quantitation of the Minor Tobacco Alkaloids Nornicotine, Anatabine, and Anabasine in Smokers' Urine by High Throughput Liquid Chromatography-Mass Spectrometry.

von Weymarn LB, Thomson NM, Donny EC, Hatsukami DK, Murphy SE.

Chem Res Toxicol. 2016 Mar 21;29(3):390-7. doi: 10.1021/acs.chemrestox.5b00521. Epub 2016 Feb 12.

37.

Randomized Trial of Reduced-Nicotine Standards for Cigarettes.

Donny EC, Hatsukami DK.

N Engl J Med. 2016 Jan 28;374(4):396-7. doi: 10.1056/NEJMc1513886. No abstract available.

38.

Providing a Science Base for the Evaluation of Tobacco Products.

Berman ML, Connolly G, Cummings KM, Djordjevic MV, Hatsukami DK, Henningfield JE, Myers M, O'Connor RJ, Parascandola M, Rees V, Rice JM, Shields PG.

Tob Regul Sci. 2015 Apr;1(1):76-93.

39.

Preference for Flavored Noncombustible Nicotine Products Among Smokers Motivated to Switch From Cigarettes.

Meier E, Isaksson Vogel R, O'Connor RJ, Severson HH, Shields PG, Hatsukami DK.

Nicotine Tob Res. 2016 May;18(5):892-3. doi: 10.1093/ntr/ntv259. Epub 2015 Nov 25. No abstract available.

40.

Measurement of the Heterocyclic Amines 2-Amino-9H-pyrido[2,3-b]indole and 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in Urine: Effects of Cigarette Smoking.

Konorev D, Koopmeiners JS, Tang Y, Franck Thompson EA, Jensen JA, Hatsukami DK, Turesky RJ.

Chem Res Toxicol. 2015 Dec 21;28(12):2390-9. doi: 10.1021/acs.chemrestox.5b00401. Epub 2015 Dec 3.

41.

Randomized Trial of Reduced-Nicotine Standards for Cigarettes.

Donny EC, Denlinger RL, Tidey JW, Koopmeiners JS, Benowitz NL, Vandrey RG, al'Absi M, Carmella SG, Cinciripini PM, Dermody SS, Drobes DJ, Hecht SS, Jensen J, Lane T, Le CT, McClernon FJ, Montoya ID, Murphy SE, Robinson JD, Stitzer ML, Strasser AA, Tindle H, Hatsukami DK.

N Engl J Med. 2015 Oct;373(14):1340-9. doi: 10.1056/NEJMsa1502403.

42.

Perceived Health Risks of Snus and Medicinal Nicotine Products.

Hatsukami DK, Vogel RI, Severson HH, Jensen JA, O'Connor RJ.

Nicotine Tob Res. 2016 May;18(5):794-800. doi: 10.1093/ntr/ntv200. Epub 2015 Sep 18.

43.

Validation of a Measure of Normative Beliefs About Smokeless Tobacco Use.

Adkison SE, O'Connor RJ, Bansal-Travers M, Cummings KM, Rees VW, Hatsukami DK.

Nicotine Tob Res. 2016 May;18(5):801-8. doi: 10.1093/ntr/ntv156. Epub 2015 Jul 17.

44.

Changes in circulating leptin levels during the initial stage of cessation are associated with smoking relapse.

Lemieux A, Nakajima M, Hatsukami DK, Allen S, al'Absi M.

Psychopharmacology (Berl). 2015 Sep;232(18):3355-61. doi: 10.1007/s00213-015-3989-8. Epub 2015 Jul 10.

45.

Psychometric Characteristics of the Brief Wisconsin Inventory of Smoking Dependence Motives Among a Nonclinical Sample of Smokers.

Adkison SE, Rees VW, Bansal-Travers M, Hatsukami DK, O'Connor RJ.

Nicotine Tob Res. 2016 Apr;18(4):470-6. doi: 10.1093/ntr/ntv113. Epub 2015 May 25.

46.

Randomised clinical trial of snus versus medicinal nicotine among smokers interested in product switching.

Hatsukami DK, Severson H, Anderson A, Vogel RI, Jensen J, Broadbent B, Murphy SE, Carmella S, Hecht SS.

Tob Control. 2016 May;25(3):267-74. doi: 10.1136/tobaccocontrol-2014-052080. Epub 2015 May 19.

47.

Self-reported Tobacco use does not correlate with carcinogen exposure in smokers with head and neck cancer.

Khariwala SS, Carmella SG, Stepanov I, Bandyopadhyay D, Nelson HH, Yueh B, Hatsukami DK, Hecht SS.

Laryngoscope. 2015 Aug;125(8):1844-8. doi: 10.1002/lary.25290. Epub 2015 Apr 15.

48.

CHRNA5 risk variant predicts delayed smoking cessation and earlier lung cancer diagnosis--a meta-analysis.

Chen LS, Hung RJ, Baker T, Horton A, Culverhouse R, Saccone N, Cheng I, Deng B, Han Y, Hansen HM, Horsman J, Kim C, Lutz S, Rosenberger A, Aben KK, Andrew AS, Breslau N, Chang SC, Dieffenbach AK, Dienemann H, Frederiksen B, Han J, Hatsukami DK, Johnson EO, Pande M, Wrensch MR, McLaughlin J, Skaug V, van der Heijden HF, Wampfler J, Wenzlaff A, Woll P, Zienolddiny S, Bickeböller H, Brenner H, Duell EJ, Haugen A, Heinrich J, Hokanson JE, Hunter DJ, Kiemeney LA, Lazarus P, Le Marchand L, Liu G, Mayordomo J, Risch A, Schwartz AG, Teare D, Wu X, Wiencke JK, Yang P, Zhang ZF, Spitz MR, Kraft P, Amos CI, Bierut LJ.

J Natl Cancer Inst. 2015 Apr 14;107(5). pii: djv100. doi: 10.1093/jnci/djv100. Print 2015 May. Review.

49.

Genetic and phenotypic variation in UGT2B17, a testosterone-metabolizing enzyme, is associated with BMI in males.

Zhu AZ, Cox LS, Ahluwalia JS, Renner CC, Hatsukami DK, Benowitz NL, Tyndale RF.

Pharmacogenet Genomics. 2015 May;25(5):263-9. doi: 10.1097/FPC.0000000000000135.

50.

The effect of tobacco additives on smoking initiation and maintenance.

Ferreira CG, Silveira D, Hatsukami DK, Paumgartten FJ, Fong GT, Glória MB, Toledo MC, Talhout R.

Cad Saude Publica. 2015 Feb;31(2):223-5. No abstract available.

Supplemental Content

Loading ...
Support Center